EuBiologics has entered into a 10.1 billion KRW supply contract with UNICEF for its oral cholera vaccine EuBicol-S. This represents 6.77% of 2025 standalone revenue with a contract period from July to September 2026.
The counterparty UNICEF is a highly credible international relief agency with stable payment terms within 30 days after document submission. Since this is a pure supply contract, no additional capital raising or share dilution is involved.
The company's financial health remains unchanged, and this contract is considered a normal business activity within its existing operations.
[AI Summary]EuBiologics' 10.1 billion KRW vaccine supply contract with UNICEF is a normal commercial agreement with a trusted counterparty, neutral to shareholder value. No capital dilution or structural financial change occurs, and the contract size at 6.77% of revenue provides positive but limited near-term earnings impact.
KOSDAQ Filing Information
Notification of Single Sales and Supply Agreement (Voluntary Disclosure)